Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-25-209153
Filing Date
2025-09-19
Accepted
2025-09-19 16:30:03
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 16214
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 98652
3 EX-99.2 ck0000000000-ex99_2.pdf EX-99.2 195224
  Complete submission text file 0001193125-25-209153.txt   423124
Mailing Address 575 MADISON AVENUE NEW YORK NY 10022
Business Address 575 MADISON AVENUE NEW YORK NY 10022 917-450-6581
LB PHARMACEUTICALS INC (Subject) CIK: 0001691082 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95235 | Film No.: 251327199
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830
Business Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830 2034090812
Deep Track Capital, LP (Filed by) CIK: 0001856083 (see all company filings)

EIN.: 853360885 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D